Alps Advisors Inc Replimune Group, Inc. Transaction History

Alps Advisors Inc

$17.2 Billion
Q1 2025

A detailed history of Alps Advisors Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 56,328 shares of REPL stock, worth $505,825. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,328

Previous 60,917 7.53%

Holding current value

$505,825

Previous $737,000 25.51%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 30, 2025	SELL	$9.75 - $14.31 $44,742 - $65,668	-4,589 Reduced 7.53%	56,328 $549,000
Q4 2024 Feb 13, 2025	BUY	$10.54 - $14.93 $90,812 - $128,636	8,616 Added 16.47%	60,917 $737,000
Q3 2024 Nov 12, 2024	BUY	$8.09 - $11.23 $35,676 - $49,524	4,410 Added 9.21%	52,301 $573,000
Q2 2024 Aug 13, 2024	BUY	$5.01 - $9.46 $23,030 - $43,487	4,597 Added 10.62%	47,891 $431,000
Q1 2024 May 14, 2024	BUY	$6.87 - $9.31 $24,182 - $32,771	3,520 Added 8.85%	43,294 $353,000
Q4 2023 Feb 14, 2024	SELL	$6.75 - $16.18 $25,488 - $61,095	-3,776 Reduced 8.67%	39,774 $335,000
Q3 2023 Nov 14, 2023	BUY	$15.96 - $22.18 $17,284 - $24,020	1,083 Added 2.55%	43,550 $745,000
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $80,441 - $123,874	5,140 Added 13.77%	42,467 $986,000
Q1 2023 May 10, 2023	BUY	$17.48 - $29.09 $63,137 - $105,073	3,612 Added 10.71%	37,327 $659,000
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $115,579 - $188,755	6,763 Added 25.09%	33,715 $917,000
Q3 2022 Nov 14, 2022	SELL	$15.6 - $21.15 $33,727 - $45,726	-2,162 Reduced 7.43%	26,952 $465,000
Q2 2022 Aug 11, 2022	SELL	$13.32 - $19.98 $258,514 - $387,771	-19,408 Reduced 40.0%	29,114 $509,000
Q1 2022 May 16, 2022	SELL	$15.24 - $29.75 $87,584 - $170,973	-5,747 Reduced 10.59%	48,522 $824,000
Q4 2021 Feb 09, 2022	SELL	$25.43 - $34.25 $77,637 - $104,565	-3,053 Reduced 5.33%	54,269 $1.47 Million
Q3 2021 Nov 15, 2021	SELL	$28.98 - $39.54 $117,803 - $160,730	-4,065 Reduced 6.62%	57,322 $1.7 Million
Q2 2021 Aug 11, 2021	SELL	$28.5 - $39.37 $620,188 - $856,730	-21,761 Reduced 26.17%	61,387 $2.36 Million
Q1 2021 May 07, 2021	BUY	$30.22 - $45.57 $55,997 - $84,441	1,853 Added 2.28%	83,148 $2.54 Million
Q4 2020 Feb 03, 2021	BUY	$23.5 - $52.65 $703,026 - $1.58 Million	29,916 Added 58.23%	81,295 $3.1 Million
Q3 2020 Nov 04, 2020	BUY	$18.85 - $27.0 $26,258 - $37,611	1,393 Added 2.79%	51,379 $1.18 Million
Q2 2020 Aug 05, 2020	SELL	$9.76 - $25.95 $145,433 - $386,680	-14,901 Reduced 22.96%	49,986 $1.24 Million
Q1 2020 May 06, 2020	SELL	$8.9 - $19.08 $67,275 - $144,225	-7,559 Reduced 10.43%	64,887 $647,000
Q4 2019 Feb 07, 2020	BUY	$11.61 - $17.21 $841,098 - $1.25 Million	72,446 New	72,446 $1.04 Million

Others Institutions Holding REPL

# of Institutions

172

Shares Held

78.5M

Call Options Held

69.4K

Put Options Held

216K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $443M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Replimune Group, Inc. Transaction History